Zoetis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. It operates through the United States and International geographical segments. 

CEO
Kristin C. Peck
CEOKristin C. Peck
Employees
14,500
Employees14,500
Headquarters
Parsippany, New Jersey
HeadquartersParsippany, New Jersey
Founded
1952
Founded1952
Employees
14,500
Employees14,500

ZTS Key Statistics

Market cap
33.08B
Market cap33.08B
Price-Earnings ratio
13.09
Price-Earnings ratio13.09
Dividend yield
2.63%
Dividend yield2.63%
Average volume
4.22M
Average volume4.22M
High today
$80.24
High today$80.24
Low today
$78.15
Low today$78.15
Open price
$79.65
Open price$79.65
Volume
3.74M
Volume3.74M
52 Week high
$148.30
52 Week high$148.30
52 Week low
$68.77
52 Week low$68.77

Stock Snapshot

With a market cap of 33.08B, Zoetis(ZTS) trades at $79.51. The stock has a price-to-earnings ratio of 13.09 and currently yields dividends of 2.63%.

During the trading session on 2026-10-20, Zoetis(ZTS) shares reached a daily high of $80.24 and a low of $78.15. At a current price of $79.51, the stock is +1.7% higher than the low and still -0.9% under the high.

Trading volume for Zoetis(ZTS) stock has reached 3.74M, versus its average volume of 4.22M.

The stock's 52-week range extends from a low of $68.77 to a high of $148.30.

The stock's 52-week range extends from a low of $68.77 to a high of $148.30.

ZTS News

TipRanks 6h
Zoetis announces FDA approval of Convenia RTU for Dogs

Zoetis (ZTS) announced that the U.S. FDA has approved Convenia RTU for Dogs for the treatment of susceptible bacterial skin infections in dogs. For many familie...

TipRanks 17h
Zoetis downgraded to Hold from Buy at Jefferies

Jefferies analyst Keith Devas downgraded Zoetis (ZTS) to Hold from Buy with a price target of $83, down from $103. The firm cites the company’s softer pricing e...

Simply Wall St 2d
Zoetis Could Be 15% Undervalued Following Its 2026 Earnings Outlook Cut

Advertisement Board appointment and earnings reset put Zoetis in focus Zoetis (ZTS) is back on investor radars after management cut its 2026 earnings outlook...

Zoetis Could Be 15% Undervalued Following Its 2026 Earnings Outlook Cut

Analyst ratings

72%

of 18 ratings
Buy
27.8%
Hold
72.2%
Sell
0%

More ZTS News

Simply Wall St 3d
Will Lower Earnings Outlook Change Zoetis Stock Narrative

Zoetis cut its 2026 earnings outlook after reporting softer demand in its U.S. companion-animal business, while livestock and international operations provided...

Will Lower Earnings Outlook Change Zoetis Stock Narrative
Simply Wall St 7d
Zoetis Stock May Sit Below Fair Value After Mixed Q2 Results

has seen its share price weaken materially in recent years, and with earnings now in the spotlight, the question is whether the current valuation still lines up...

Zoetis Stock May Sit Below Fair Value After Mixed Q2 Results

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.